liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.
Company profile
Ticker
LQDA
Exchange
Website
CEO
Neal Fowler
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Liquidia Technologies, Inc. • Liquidia PAH, LLC ...
IRS number
851710962
LQDA stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
12 Apr 24
8-K
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
1 Apr 24
S-8
Registration of securities for employees
13 Mar 24
S-8
Registration of securities for employees
13 Mar 24
10-K
2023 FY
Annual report
13 Mar 24
8-K
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
13 Mar 24
8-K
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
25 Jan 24
8-K
Other Events
23 Jan 24
8-K
Liquidia Corporation Announces Updates to Operations Leadership
19 Jan 24
8-K
Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
8 Jan 24
Transcripts
LQDA
Earnings call transcript
2023 Q3
7 Nov 23
LQDA
Earnings call transcript
2023 Q2
10 Aug 23
LQDA
Earnings call transcript
2023 Q1
4 May 23
LQDA
Earnings call transcript
2023 Q1
4 May 23
LQDA
Earnings call transcript
2022 Q4
16 Mar 23
LQDA
Earnings call transcript
2022 Q3
8 Nov 22
LQDA
Earnings call transcript
2022 Q2
11 Aug 22
LQDA
Earnings call transcript
2022 Q1
12 May 22
LQDA
Earnings call transcript
2021 Q4
17 Mar 22
LQDA
Earnings call transcript
2021 Q2
10 Aug 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 76.23 mm | 76.23 mm | 76.23 mm | 76.23 mm | 76.23 mm | 76.23 mm |
Cash burn (monthly) | 3.99 mm | 1.84 mm | 4.96 mm | 4.45 mm | 3.85 mm | 2.52 mm |
Cash used (since last report) | 27.26 mm | 12.58 mm | 33.91 mm | 30.43 mm | 26.33 mm | 17.19 mm |
Cash remaining | 48.96 mm | 63.65 mm | 42.31 mm | 45.80 mm | 49.90 mm | 59.04 mm |
Runway (months of cash) | 12.3 | 34.6 | 8.5 | 10.3 | 12.9 | 23.5 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Apr 24 | Rajeev Saggar | Common Stock | Sell | Dispose S | No | Yes | 13.68 | 1,649 | 22.56 k | 211,672 |
12 Apr 24 | Michael Kaseta | Common Stock | Sell | Dispose S | No | Yes | 14.58 | 3,136 | 45.72 k | 315,045 |
12 Apr 24 | Jeffs Roger | Common Stock | Sell | Dispose S | No | Yes | 14.58 | 8,360 | 121.89 k | 826,985 |
12 Apr 24 | Scott Moomaw | Common Stock | Sell | Dispose S | No | Yes | 14.58 | 1,585 | 23.11 k | 151,881 |
12 Apr 24 | Rajeev Saggar | Common Stock | Sell | Dispose S | No | Yes | 14.58 | 1,525 | 22.23 k | 213,321 |
News
Needham Reiterates Buy on Liquidia, Maintains $28 Price Target
10 Apr 24
The Analyst Landscape: 5 Takes On Liquidia
1 Apr 24
Needham Reiterates Buy on Liquidia, Maintains $28 Price Target
1 Apr 24
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
27 Mar 24
10 Health Care Stocks Whale Activity In Today's Session
18 Mar 24
Press releases
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
2 Apr 24
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
1 Apr 24
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
13 Mar 24
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
6 Mar 24
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
30 Jan 24